[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic]

Prog Urol. 2021 Apr;31(5):243-244. doi: 10.1016/j.purol.2020.12.002. Epub 2020 Dec 10.
[Article in French]
No abstract available

Keywords: Abiraterone acetate; Acétate d’abiratérone; COVID-19 pandemic; Corticotherapy; Corticothérapie; Pandémie COVID-19.

Publication types

  • Letter
  • Review

MeSH terms

  • Abiraterone Acetate / administration & dosage
  • Abiraterone Acetate / adverse effects*
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects*
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / adverse effects*
  • Androgens
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • COVID-19* / therapy
  • Contraindications, Drug
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Male
  • Meta-Analysis as Topic
  • Neoplasms, Hormone-Dependent / drug therapy
  • Oxygen / therapeutic use
  • Pandemics*
  • Practice Guidelines as Topic
  • Prospective Studies
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms, Castration-Resistant / drug therapy
  • Randomized Controlled Trials as Topic
  • Respiration, Artificial
  • Risk
  • SARS-CoV-2*

Substances

  • Adrenal Cortex Hormones
  • Androgen Antagonists
  • Androgens
  • Antineoplastic Agents, Hormonal
  • Immunosuppressive Agents
  • Abiraterone Acetate
  • Oxygen